Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study

Basit Öğe Kaydı
dc.contributor.authorSeckin, D.
dc.contributor.authorGurbuz, O.
dc.contributor.authorAkin, O.
dc.date.accessioned2024-07-12T21:51:34Z
dc.date.available2024-07-12T21:51:34Z
dc.date.issued2007en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractBackground Recently, two placebo-controlled studies have shown that topical metronidazole was effective in the treatment of seborrheic dermatitis. Objective To compare the efficacy and safety of metronidazole 0.75% gel with that of ketoconazole 2% cream in the treatment of facial seborrheic dermatitis. Methods A total of 60 consecutive patients with facial seborrheic dermatitis were included. Patients were randomized into two groups. One group used ketoconazole 2% cream with metronidazole gel as vehicle; the other group used metronidazole 0.75% gel with ketoconazole cream as vehicle for a 4-week treatment period. Main outcome measures were change in clinical severity scores, patients' and investigator's global evaluation of improvement and frequency of side-effects. Results All the assessments were made by an investigator who was unaware of which group the patients were allocated to. Mean percentage decrease in clinical severity scores from baseline to last available visit was 63.4% (95% CI 57.7-69) and 54.4% (95% CI 47.9-61) in the ketoconazole- and metronidazole-treated patients, respectively (P = 0.31). Eighty-two per cent of patients in the ketoconazole group vs. 79% of patients in the metronidazole group rated their global improvement as significant or moderate (P > 0.05). No statistically significant difference in the frequency of side-effects was detected between the two groups. The results of this study need to be confirmed in further studies involving large numbers of patients. Conclusion Our data demonstrated that metronidazole 0.75% gel had a comparable efficacy and safety profile with that of ketoconazole 2% cream in the treatment of facial seborrheic dermatitis.en_US
dc.identifier.doi10.1111/j.1468-3083.2006.01927.x
dc.identifier.endpage350en_US
dc.identifier.issn0926-9959
dc.identifier.issue3en_US
dc.identifier.pmid17309456en_US
dc.identifier.scopus2-s2.0-33846967787en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage345en_US
dc.identifier.urihttps://dx.doi.org/10.1111/j.1468-3083.2006.01927.x
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8278
dc.identifier.volume21en_US
dc.identifier.wosWOS:000244244200008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBLACKWELL PUBLISHINGen_US
dc.relation.ispartofJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY02061
dc.subjectketoconazoleen_US
dc.subjectmetronidazoleen_US
dc.subjectseborrheic dermatitisen_US
dc.subjecttreatmenten_US
dc.titleMetronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind studyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu